Is Retatrutide the Next Big GLP-1 Peptide? Early Research Breakdown

Semaglutide changed the conversation around medical weight loss. Then came tirzepatide, which pushed the results even further.

Now another peptide is attracting attention: retatrutide.

Early clinical trials showed unusually large reductions in body weight. More recent Phase 3 results have made the interest even stronger, with people taking the highest studied dose losing an average of 28.3% of their body weight after 80 weeks in TRIUMPH-1. 

But retatrutide is not simply another GLP-1 drug.

It works on three hormone receptors at the same time, which may explain why it has produced such large weight loss results.

So, what do we actually know about retatrutide so far?

And how does it compare with semaglutide and tirzepatide?

Here is what the clinical research shows.

What Is Retatrutide?

Retatrutide is an investigational peptide being developed as a once weekly injection.

It is sometimes described as a “triple agonist” because it activates three hormone receptors:

• GLP-1
• GIP
• Glucagon

GLP-1 and GIP are already familiar from existing weight loss and diabetes medications. Glucagon adds a third pathway that may influence energy use and fat metabolism.

Researchers believe that combining these three pathways could produce a stronger effect on body weight than targeting GLP-1 alone.

Importantly, retatrutide is not currently approved for routine medical use. It remains an investigational treatment being studied in clinical trials. 

How Does Retatrutide Work?

The easiest way to understand retatrutide is to look at the three receptors it targets.

GLP-1

GLP-1 can reduce appetite and slow the movement of food through the stomach. This can help people feel full for longer and eat less.

GIP

GIP is another hormone involved in blood sugar regulation and metabolism. When combined with GLP-1 activity, it may contribute to improved glucose control and weight reduction.

Glucagon

Glucagon works differently.

It can increase energy expenditure and influence how the body uses stored energy. Researchers are particularly interested in this pathway because it may add another layer of weight loss beyond appetite reduction.

The idea behind retatrutide is therefore not simply to make one pathway stronger. It is to combine three different hormonal signals in one treatment.

Early research suggests this combination may have a meaningful effect on body weight. 

What Did the Phase 2 Trial Show?

The first major human evidence came from a Phase 2 clinical trial published in the New England Journal of Medicine in 2023.

The study included 338 adults with obesity or overweight plus a weight related condition. Participants received different doses of retatrutide or placebo once weekly for 48 weeks. At 48 weeks, the highest dose produced an average weight reduction of 24.2%.

For comparison:

• 4 mg produced about 17.1% weight loss
• 8 mg produced about 22.8%
• 12 mg produced about 24.2%
• Placebo produced about 2.1%

The 12 mg group also showed a particularly high percentage of people reaching major weight loss thresholds.

Around 83% achieved at least 15% weight loss, while 26% lost 30% or more of their starting body weight. 

These were Phase 2 results, so they needed to be confirmed in larger and longer studies. That is exactly what the later Phase 3 program was designed to do.

What Did the Phase 3 TRIUMPH Trials Show?

The Phase 3 results have made retatrutide even more interesting.

TRIUMPH-1

TRIUMPH-1 evaluated retatrutide in adults with obesity or overweight and at least one weight related condition, without diabetes.

After 80 weeks:

• 4 mg: 19.0% average weight loss
• 9 mg: 25.9%
• 12 mg: 28.3%
• Placebo: 2.2%

At the 12 mg dose, 45.3% of participants lost at least 30% of their body weight. An extension of the study also found that participants with a baseline BMI of at least 35 continued losing weight, reaching an average reduction of up to 30.3% at 104 weeks. 

These numbers are one reason retatrutide has attracted so much attention.

TRIUMPH-4

TRIUMPH-4 looked at adults with obesity or overweight and knee osteoarthritis.

At 68 weeks, people taking 12 mg of retatrutide lost an average of 28.7% of their body weight, or about 71.2 pounds in the study population. 

The study also found substantial improvements in knee pain and physical function.

At the 12 mg dose, the average reduction in the WOMAC pain score was 75.8% from baseline. 

This does not mean retatrutide should be viewed as a treatment for knee pain by itself. Much of the improvement may be related to the substantial weight loss and its effect on the joints.

Still, the findings are important because obesity and osteoarthritis often occur together.

How Does Retatrutide Compare With Other GLP-1 Drugs?

It is tempting to compare retatrutide directly with semaglutide or tirzepatide.

But there is an important limitation.

Most of the available studies were conducted separately, with different participants, doses, treatment periods, and study designs.

That means you cannot simply take the biggest number from each trial and declare one drug the winner.

A 2025 Bayesian network meta-analysis looked at 19 randomized trials involving 29,506 adults and compared GLP-1 receptor agonists, dual agonists, retatrutide, and placebo. 

The analysis found that retatrutide had particularly strong results for achieving at least 15% weight loss.

The odds ratio for reaching that threshold was:

• Retatrutide: 54.6
• Dual agonists: 16.4
• GLP-1 receptor agonists: 9.0

However, the analysis also found that retatrutide had the highest adverse event risk among the treatments included. 

This is an important point. Greater weight loss does not automatically mean a treatment is better for every person.

What Are the Side Effects of Retatrutide?

So far, the side effects reported with retatrutide have generally looked similar to those seen with other incretin based medications.

The most common include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Reduced appetite
• Other gastrointestinal symptoms

In the Phase 2 trial, gastrointestinal side effects were the most common and were generally mild to moderate. They were also related to the dose. 

TRIUMPH-4 showed the same general pattern. At 12 mg, nausea occurred in 43.2% of participants, diarrhea in 33.1%, constipation in 25.0%, and vomiting in 20.9%. 

Another finding worth watching is heart rate.

The Phase 2 trial reported dose dependent increases in heart rate, which peaked around 24 weeks and then declined. 

This is one reason the safety profile of retatrutide needs to be evaluated alongside its impressive weight loss results.

Retatrutide and Type 2 Diabetes

Retatrutide is also being studied in people with type 2 diabetes.

In the Phase 3 TRANSCEND-T2D-1 trial, participants receiving 12 mg lost an average of 16.8% of their body weight after 40 weeks.

The treatment also reduced HbA1c by up to 2.0%, depending on the dose. Interestingly, researchers reported that weight loss had not yet reached a clear plateau at 40 weeks.

That suggests longer treatment may produce additional changes, although longer term data is still needed.

Why Does the Triple Receptor Mechanism Matter?

This is probably the most interesting part of retatrutide.

Semaglutide primarily targets the GLP-1 receptor.

Tirzepatide targets both GLP-1 and GIP.

Retatrutide adds glucagon to those two pathways.

The goal is to combine several effects:

GLP-1 → appetite and food intake

GIP → metabolic and glucose related effects

Glucagon → energy expenditure and fuel use

The theory is that these pathways may complement each other.

The clinical results so far suggest that this approach can produce substantial weight loss.

But researchers still need to understand exactly how much of the additional benefit comes from the third pathway and how that benefit balances against tolerability and long term safety.

That is why direct comparisons with existing treatments matter so much.

Is Retatrutide Approved Yet?

No.

Retatrutide remains an investigational medication and is not currently approved by the FDA.

Eli Lilly states that retatrutide is still being evaluated in clinical trials and that it has not been approved by a regulatory agency. 

This also means products sold online as “retatrutide” should not be confused with an approved prescription medication.

Lilly specifically warns that retatrutide obtained outside clinical trials cannot be assumed to have verified safety, purity, or dosing. 

Frequently Asked Questions

Is retatrutide better than semaglutide?

Current clinical data suggests that retatrutide can produce greater average weight loss than semaglutide in separate trials. However, there has not been a direct head to head trial establishing that retatrutide is better for every patient.

Is retatrutide better than tirzepatide?

Retatrutide has produced very large weight loss numbers in Phase 3 trials, but separate trial results should not be treated as a direct comparison. A head to head study against tirzepatide is more useful for answering this question.

When will retatrutide be available?

Retatrutide is still investigational and is not approved for general use. Its availability will depend on the completion of clinical development and regulatory review. 

What makes retatrutide different from other GLP-1 drugs?

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. This triple mechanism is the main feature that separates it from treatments that target only GLP-1 or GLP-1 plus GIP.

Does retatrutide cause side effects?

Yes. Clinical trials have reported gastrointestinal side effects such as nausea, diarrhea, constipation, and vomiting. Higher doses tend to produce more side effects, which is why gradual dose escalation is used in clinical studies. 

Conclusion

Retatrutide has quickly become one of the most closely watched investigational treatments in obesity research.

The reason is simple: the weight loss seen in clinical trials is substantial. In TRIUMPH-1, the 12 mg dose produced an average 28.3% reduction in body weight after 80 weeks, while TRIUMPH-4 produced 28.7% after 68 weeks in people with obesity and knee osteoarthritis. 

But impressive results do not answer every question.

Retatrutide is still being studied, it is not approved for routine use, and its long term safety and place alongside existing treatments still need to be established.

For now, the evidence makes one thing clear:

Retatrutide is not just another GLP-1 peptide. It represents a different approach to weight management, and the Phase 3 data is giving researchers plenty of reasons to keep watching.